Article

Pharmacotherapy for Social Anxiety Disorder and Specific Phobia

Michael Van Ameringen, Catherine Mancini and Beth Patterson

in Oxford Handbook of Anxiety and Related Disorders

Published in print September 2008 | ISBN: 9780195307030
Published online September 2012 | | DOI: http://dx.doi.org/10.1093/oxfordhb/9780195307030.013.0024

Series: Oxford Library of Psychology

 Pharmacotherapy for Social Anxiety Disorder and Specific Phobia

More Like This

Show all results sharing these subjects:

  • Psychology
  • Clinical Psychology

GO

Show Summary Details

Preview

This chapter examines how, over the past two decades, there has been a rapid emergence of pharmacological treatment options for patients with generalized social anxiety disorder (GSAD). Results of treatment and neuroimaging studies suggest the involvement of serotonin, gamma-amino-butyric acid (GABA)/glutamate, and dopamine in GSAD. The literature clearly supports the use of SSRIs and the SNRI venlafaxine ER as first-line pharmacological agents in the treatment of GSAD; however, there is a paucity of data for patients who obtain a partial or nonresponse to first-line treatments as well as strategies to move GSAD individuals from response to remission. Exposure-based treatments are considered to be the gold standard treatment for specific phobias. There is a small literature on the use of pharmacological agents in specific phobias that does not support their use as the primary treatment modality.

Keywords: anxiety; anxiety treatment; pharmacotherapy; social anxiety; social phobia; treatment resistance

Article.  8603 words. 

Subjects: Psychology ; Clinical Psychology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.